Lucid Diagnostics (LUCD) EBITDA (2020 - 2026)

Lucid Diagnostics (LUCD) has 7 years of EBITDA data on file, last reported at -$12.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 2.99% year-over-year to -$12.1 million; the trailing twelve-month figure through Mar 2026 stood at -$11.8 million (up 75.27% YoY), and the FY2025 full-year result was -$12.2 million, up 73.55% from the prior year.
• EBITDA for Q1 2026 stood at -$12.1 million, down from $23.4 million in the prior quarter.
• Across five years, EBITDA topped out at $23.4 million in Q4 2025 and bottomed at -$15.0 million in Q4 2022.
• The 5-year median for EBITDA is -$11.8 million (2025), against an average of -$10.3 million.
• The widest annual swing landed in 2022, when EBITDA sank 235.92%; it then soared 289.47% in 2025.
• A 5-year view of EBITDA shows it stood at -$15.0 million in 2022, then advanced by 23.52% to -$11.5 million in 2023, then fell by 8.05% to -$12.4 million in 2024, then jumped by 289.47% to $23.4 million in 2025, then tumbled by 151.67% to -$12.1 million in 2026.
• The last three EBITDA figures came in at -$12.1 million (Q1 2026), $23.4 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.

Peer Comparison